American journal of clinical oncology
Efficacy and Safety of Antibody Drug Conjugates in Previously Treated Hormone Receptor Positive HER2 Negative (or Low) Metastatic Breast Cancer-A Systematic Review and Meta-Analysis.
Yijin Huang, Dingde Ye, Fazal Hassan, Mary J Hart, Qingxiang Xu
Published: 202510.1097/COC.0000000000001259
Abstract
OBJECTIVES: Antibody-drug conjugates (ADCs) have improved outcomes for metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 (HER2)-negative or low breast cancer; however, direct efficacy comparisons are limited. We…
Preview only. Read the full abstract at the source